Lisata Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 25
- Market Cap
- -
- Website
- http://www.lisata.com
- Introduction
Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.
Clinical Trials
17
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
- Conditions
- Pancreas CancerPancreatic CarcinomaPancreas AdenocarcinomaPancreatic Ductal AdenocarcinomaUnresectable Pancreatic CancerMetastatic Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06592664
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
- Conditions
- CholangiocarcinomaIntrahepatic CholangiocarcinomaGall Bladder CancerGallbladder CancerExtrahepatic CholangiocarcinomaBile Duct CancerGall Bladder CarcinomaGallbladder Carcinoma
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05712356
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04990427
- Locations
- 🇺🇸
Clinical Advancement Center, PLLC, San Antonio, Texas, United States
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
- Conditions
- Coronary Microvascular DiseaseMicrovascular Coronary Artery DiseaseCoronary Microvascular Dysfunction
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04614467
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Florida - College of Medicine/ div of Cardiovascular Medicine, Gainesville, Florida, United States
🇺🇸Memorial Regional Hospital, Hollywood, Florida, United States
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Registration Number
- NCT04522817
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
Lisata Therapeutics Reports Promising 60% Response Rate in Pancreatic Cancer Trial with Certepetide
Lisata Therapeutics and WARPNINE completed enrollment in the Phase 1b/2a iLSTA trial evaluating certepetide in combination with standard-of-care therapy for locally advanced pancreatic ductal adenocarcinoma.
Lisata Therapeutics Secures Composition of Matter Patent for Certepetide Through 2040
Lisata Therapeutics received a new U.S. composition of matter patent for certepetide extending intellectual property protection through March 2040, with potential for further extension.
Endometriosis Pain Treatment Pipeline Shows Mixed Results as NHS Approves First Daily Oral Therapy
The NHS in England has approved relugolix combination therapy as the first long-term daily oral treatment for endometriosis, expected to benefit around 1,000 women annually whose symptoms persist despite previous treatments.
Lisata's Certepetide Shows Promising Results in Phase 2b Pancreatic Cancer Trial
Lisata Therapeutics' certepetide demonstrated significant improvements in progression-free survival and response rates when combined with standard chemotherapy in metastatic pancreatic cancer patients.
Critical Limb Ischemia Market Projected to Reach $2.5 Billion by 2035, Driven by Novel Therapies and Advanced Diagnostics
The critical limb ischemia (CLI) market is expected to grow from $1.4 billion in 2024 to $2.5 billion by 2035, with a CAGR of 6.66%, fueled by advances in early detection technologies and personalized medicine approaches.
Lisata and GATC Health Partner to Accelerate Drug Development Using AI Platform
Lisata Therapeutics and GATC Health launch strategic collaboration utilizing GATC's AI-powered Multiomics Advanced Technology platform to optimize drug development and improve success rates.
Endometriosis Clinical Trial Pipeline Shows Promise with 20+ Therapies in Development
The endometriosis clinical trial landscape is robust, featuring over 15 companies developing more than 20 potential therapies.
Lisata Therapeutics Completes Enrollment in CENDIFOX Trial of Certepetide for Advanced Solid Tumors
Lisata Therapeutics has completed enrollment in the Phase 1b/2a CENDIFOX trial evaluating certepetide combined with FOLFIRINOX-based therapies.
Lisata Therapeutics Advances Clinical Trials, Anticipates Data-Rich 2025
Lisata Therapeutics is actively progressing its clinical trials, with significant data readouts expected in 2025, marking a potentially transformative period for the company.
Certepetide Shows Promise in Metastatic Pancreatic Cancer: Lisata Therapeutics Announces Encouraging Phase 2 Results
Lisata Therapeutics reported positive trends in overall survival for certepetide plus chemotherapy in metastatic pancreatic cancer patients.